BioNTech SE
- Last sale
- Nov 12, 2026 · -2.99%
- Market cap
- $21.50B
- 252.88M shares
- Filings
- 590
FY 2025+4.3% FY25 yoy
FY 2025N/M FY25 yoy
FY 2025N/M FY25 yoy
FY 2025derivedN/M FY25 yoy
FY 2025N/M FY25 yoy
FY 2025−21.4% FY25 yoy
- $21.50B
- —
- —
- —
- —
- —
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | €2,869,900,000 | reported | |
| FY 2024 | 2024-12-31 | €2,751,100,000 | reported | |
| FY 2023 | 2023-12-31 | €3,819,000,000 | reported | |
| FY 2022 | 2022-12-31 | €17,310,600,000 | reported | |
| FY 2021 | 2021-12-31 | €18,976,700,000 | reported | |
| FY 2020 | 2020-12-31 | €482,300,000 | reported | |
| FY 2019 | 2019-12-31 | €108,600,000 | reported | |
| FY 2018 | 2018-12-31 | €127,575,000 | reported | |
| FY 2017 | 2017-12-31 | €61,598,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2024 | €0.00 | — | €0.00 | — | 239.97M sh | +0.9% | — |
| FY2023 | €0.00 | — | €0.00 | — | 237.73M sh | −1.4% | 0.0% |
| FY2022 | €484.30M | — | €484.30M | — | 240.99M sh | −2.4% | 3.7% |
| FY2021 | €0.00 | — | €0.00 | — | 246.81M sh | −99.9% | 0.0% |
| FY2020 | €0.00 | — | €0.00 | — | 241.52B sh | +6.5% | — |
Segments
Products
LineFY2023ShareChange
Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine€27.30M4.6%—
Commercial revenues———
Total€599.80M
Biological products, except diagnostic substances
BioNTech SE is the 7th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
RVMDRevolution Medicines, Inc.$0.0——$38.1BBIIBBiogen Inc.$9.9B2.2%13.1%$37.0B
BNTXBioNTech SE (this company)———$21.5B
NBIXNeurocrine Biosciences Inc$2.9B21.4%16.7%$17.1BEXELExelixis, Inc.$2.3B7.0%33.7%$17.0BHALOHalozyme Therapeutics, Inc.$1.4B37.6%22.7%$11.5BTECHBio-Techne Corp$1.2B0.4%15.0%$11.4BQGENQiagen N.V.$2.1B5.7%20.3%$10.9BKYMRKymera Therapeutics, Inc.$39.2M16.7%794.0%$10.9BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
BioNTech SE · CIK 1776985 · Engraved from SEC EDGAR